Oryzon Nominates Specific LSD1 Inhibitor as Drug Candidate to Enter Preclinical Development in Acute Leukemia and Other Hematological Cancers


Barcelona, Spain (PRWEB) May 24, 2012

Oryzon announced today that it is entering preclinical development with its second drug candidate, a first-in-class specific Lysine Specific Demethylase 1 (LSD1) inhibitor for the treatment of hematological cancers. Our LSD1 inhibitors reduced tumor load especially in acute leukemia models by targeting Leukemia Stem Cells, while normal myeloid progenitor cells were spared.

Lysine specific demethylase 1 (LSD1) is an enzyme that removes methyl groups from lysine 4 of histone H3 proteins that organize the nucleosomes, an epigenetic modification that leads to a repression of transcriptional activity of the target genes. LSD1 has been suggested as a possible target for cancer, viral infections and neurodegenerative disorders.

Oryzons LSD1 advanced leads were efficacious in the treatment of Acute Lymphoblastic Leukemia (ALLs), which represents 25% of juvenile leukemia, and in certain types of multiple myeloma and Chronic Lymphocytic leukemia. Independently, Oryzon

This entry was posted in Mao and tagged , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply